ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
G4-Ligand-Directed PROTACs Unveil DR1 as a Novel Ligand-Co-Binding G4-Protein and Reshape G4-Dependent Transcription.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
G-quadruplexes (G4s) are dynamic nucleic acid structures whose biological impact is largely mediated by G4-binding proteins (G4BPs). While numerous G4BPs have been catalogued, the subset that specifically co-bind G4s in the presence of small-molecule ligands remains unexplored, limiting our understanding of ligand pharmacology. Here, we introduce G4-Ligand-Directed PROTACs (G4L-TACs), a chemical biology platform that couples high-affinity G4 ligands with E3 ubiquitin ligase recruiters to selectively degrade ligand-co-binding G4BPs. Using PDS-derived G4L-TACs, we identified the transcription factor DR1 as a previously unrecognized G4BP recruited to ligand-stabilized promoter G4s. G4L-TAC-mediated DR1 degradation relieved transcriptional repression at G4-rich oncogenic promoters, providing mechanistic insights into how G4 ligands influence gene expression beyond simple nucleic acid stabilization. These results establish G4L-TACs as a novel platform to discover ligand-co-binding G4BPs and reveal DR1 as a new regulatory node in G4-dependent transcription, offering a versatile tool for mechanistic dissection and therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.